Activin Receptor Type I (ACRV1) (AA 132-161), (Center) antibody

Details for Product No. ABIN657777
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Acvr, Alk8, Alk-2, Tsk7L, ActR-I, ActRIA, Acvrlk2, D330013D15Rik, ActR-IA
AA 132-161, Center
(15), (7), (5), (4), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1)
(46), (25), (5), (3), (2), (1)
(44), (7), (3), (1)
Clonality (Clone)
Polyclonal ()
(4), (2), (1)
Western Blotting (WB)
(54), (23), (17), (16), (5), (4), (1), (1)
Pubmed 4 references available
Catalog no. ABIN657777
Quantity 400 µL
291.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This ACVR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 132-161 AA from the Central region of human ACVR1.
Clone RB33883
Isotype Ig
Specificity This ACVR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 131-161 amino acids from the Central region of human ACVR1.
Predicted Reactivity Cow (Bovine),Mouse (Murine),Rat (Rattus)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name ACVR1
Background Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive.
Synonyms: Activin receptor type-1,ACVR1,ACVRLK2
Molecular Weight 57153 DA
Gene ID 90
UniProt Q04771, NP_001104537.1, NP_001096.1
Research Area Phospho-specific antibodies, Cell Signaling, Cell Structure, Protein Modifications, Chromatin, Signaling
Application Notes WB = 1:1000
Restrictions For Research Use only
Format Liquid
Concentration 0.47 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment ACVR1 Antibody (Center) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, place the at -20 °C.
Expiry Date 6 months
Supplier Images
anti-Activin Receptor Type I (ACRV1) (AA 132-161), (Center) antibody Western blot analysis of ACVR1 (arrow) using rabbit polyclonal ACVR1 Antibody (Center) (ABIN657777). 293 cell lysates (2 µg/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the ACVR1 gene.
Background publications Herrera, van Dinther, Ten Dijke et al.: "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation." in: Cancer research, Vol. 69, Issue 24, pp. 9254-62, 2009 (PubMed).

Song, Kim, Woo et al.: "Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva." in: The Journal of biological chemistry, Vol. 285, Issue 29, pp. 22542-53, 2010 (PubMed).

Canzian, Cox, Setiawan et al.: "Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium." in: Human molecular genetics, Vol. 19, Issue 19, pp. 3873-84, 2010 (PubMed).

Shimada, Miyagawa, Kawashima et al.: "An approach based on a genome-wide association study reveals candidate loci for narcolepsy." in: Human genetics, Vol. 128, Issue 4, pp. 433-41, 2010 (PubMed).

Hosts (44), (7), (3), (1)
Reactivities (46), (25), (5), (3), (2), (1)
Applications (54), (23), (17), (16), (5), (4), (1), (1)
Conjugates (4), (2), (1)
Epitopes (15), (7), (5), (4), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top